SCHEMBL30516374

SCHEMBL30516374

CC(C)(C)OC(=O)N1CCN(c2cccc(NCc3cccc(F)c3)c2N)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.49
GPR119 Q8TDV5 1/20 0.48
ACHE P22303 2/20 0.47
MET P08581 1/20 0.46
KCNQ2 O43526 1/20 0.45
SMARCA2 P51531 1/20 0.42
SMARCA4 P51532 1/20 0.42
PBRM1 Q86U86 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
BACE1 P56817 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP2C19 P33261 1/20 0.40
MAPK8 P45983 1/20 0.40
NPC1 O15118 1/20 0.40
NPY2R P49146 1/20 0.40
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 2/20 0.39
DNMT3A Q9Y6K1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22712832 1.00 CCNT1 (0.49) CCNT1GPR119ACHEMETKCNQ2
SCHEMBL30516382 0.90 KCNQ2 (0.45) CCNT1ACHEMETKCNQ2SMARCA2
SCHEMBL21302003 0.90 KCNQ2 (0.45) CCNT1ACHEMETKCNQ2SMARCA2
SCHEMBL31066764 0.89 ACHE (0.58) GPR119ACHEMETSMARCA2SMARCA4
SCHEMBL3853111 0.89 ACHE (0.58) GPR119ACHEMETSMARCA2SMARCA4
SCHEMBL4614786 0.89 CCNT1 (0.48) CCNT1GPR119ACHEMETKCNQ2
SCHEMBL21301932 0.89 ACHE (0.47) CCNT1ACHEMETKCNQ2SMARCA2
SCHEMBL30516377 0.89 ACHE (0.47) CCNT1ACHEMETKCNQ2SMARCA2
SCHEMBL14559319 0.88 CCNT1 (0.46) CCNT1GPR119ACHEMETSMARCA2
SCHEMBL21301987 0.87 P2RX7 (0.46) CCNT1ACHEMETSMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C CCNT1 3146/4885GPR119 105/4885ACHE 287/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C CCNT1 3189/4885GPR119 120/4885ACHE 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.